7 recruiting, 2 not yet recruiting, 1 terminated. 5 Phase 1, 4 Phase 2, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 4, Terminated 1 |
| Phase 2 | 4 | Not yet recruiting 2, Recruiting 1, Terminated 1 |
| Phase 3 | 2 | Recruiting 2 |
| Not applicable | 1 | Recruiting 1 |
Follow Relapsed or Refractory Multiple Myeloma (RRMM): new trials by email Literature Review of Relapsed or Refractory Multiple Myeloma (RRMM) trials Research Report on Relapsed or Refractory Multiple Myeloma (RRMM)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma YKST02 - Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 2 | Not yet recruiting | Excyte Biopharma Ltd | 64 | 2026-09-01 | 2026-07-10 |
| In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma Invivo CAR-T - Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 15 | 2026-07-31 | 2026-07-20 |
| A Phase 2, Single Arm Multicenter, Study Testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Administration of a combination of treatments - Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 70 | 2026-02-01 | 2026-01-16 |
| A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd) - Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 3 | Recruiting | Shandong New Time Pharmaceutical Co., LTD | 261 | 2026-01-25 | 2026-05-12 |
| Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration Dual-targeting BCMA-GPRC5D CAR-T cell infusion - Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 1 | Recruiting | Beijing GoBroad Hospital | 18 | 2025-05-25 | 2025-11-26 |
| Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration Dual-targeting BCMA-CD19 CAR-T cell infusion - Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 1 | Recruiting | Beijing GoBroad Hospital | 18 | 2025-05-25 | 2025-11-26 |
| Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis - Lymphoblastic Leukemia, Relapsed or Refractory Multiple Myeloma (RRMM) | Not applicable | Recruiting | Anhui Provincial Hospital | 18 | 2025-04-16 | 2025-05-29 |
| A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) BMS-986393, Cyclophosphamide, Fludarabine - Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 3 | Recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 440 | 2025-03-12 | 2026-09-15 |
| Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Purinostat Mesylate 4 mg/m2, Purinostat Mesylate 6 mg/m2, Purinostat Mesylate 8.4 mg/m2 - Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | Recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 144 | 2024-03-25 | 2025-04-02 |
| GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies GEN3014, Daratumumab - Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Terminated | Genmab | 130 | 2021-03-09 | 2026-05-19 |
Multiple Myeloma (10) · Recurrence (10) · Leukemia, Myeloid, Acute (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Blood Protein Disorders (10) · Cardiovascular Diseases (10) · Disease Attributes (10) · Hematologic Diseases (10) · Hemic and Lymphatic Diseases (10) · Hemorrhagic Disorders (10) · Hemostatic Disorders (10) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Lymphoproliferative Disorders (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Neoplasms, Plasma Cell (10) · Paraproteinemias (10) · Pathologic Processes (10)
Dexamethasone (2) · daratumumab (2) · pomalidomide (2) · Bortezomib (1) · Cyclophosphamide (1) · carfilzomib (1) · fludarabine (1) · selinexor (1)
Beijing GoBroad Hospital (2) · Anhui Provincial Hospital (1) · Assistance Publique - Hôpitaux de Paris (1) · Chengdu Zenitar Biomedical Technology Co., Ltd (1) · Chongqing Precision Biotech Co., Ltd (1) · Excyte Biopharma Ltd (1) · Genmab (1) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (1) · Shandong New Time Pharmaceutical Co., LTD (1)
China (7) · France (3) · Australia (2) · Czechia (2) · Denmark (2) · Greece (2) · Hungary (2) · Netherlands (2) · Poland (2) · South Korea (2) · Spain (2) · Sweden (2) · United States (2) · Argentina (1) · Austria (1)
Ting Niu, Doctor (1)
2023 (1)